ActiveSight Signs Expanded Crystallography Service Agreement with Lexicon Pharmaceuticals
News Jan 09, 2007
ActiveSight announced that it has signed an expanded crystallography services agreement with Lexicon Pharmaceuticals. The agreement, the third between the companies, covers co-crystallography services for multiple proprietary targets of Lexicon Pharmaceuticals.
ActiveSight's second co-crystallography agreement with Lexicon was announced in April of 2005. Lexicon Pharmaceuticals is the medicinal chemistry division of Lexicon Genetics Incorporated.
"We are delighted that Lexicon Pharmaceuticals has decided to expand their relationship with ActiveSight. We look forward to providing continued structural biology support for Lexicon's drug discovery programs," stated Duncan McRee, President of ActiveSight.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019